TR200001706T2 - Fosfodiester IV inhibisyonuna sahip purin türevleri - Google Patents

Fosfodiester IV inhibisyonuna sahip purin türevleri

Info

Publication number
TR200001706T2
TR200001706T2 TR2000/01706T TR200001706T TR200001706T2 TR 200001706 T2 TR200001706 T2 TR 200001706T2 TR 2000/01706 T TR2000/01706 T TR 2000/01706T TR 200001706 T TR200001706 T TR 200001706T TR 200001706 T2 TR200001706 T2 TR 200001706T2
Authority
TR
Turkey
Prior art keywords
alkyl
cycloalkylalkyl
alkenyl
benzyl
phosphodiester
Prior art date
Application number
TR2000/01706T
Other languages
English (en)
Inventor
Cavalla David
Chasin Mark
Hofer Peter
Gehrig Andre
Wintergerst Peter
Original Assignee
Euro-Celtioue, S.A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Euro-Celtioue, S.A filed Critical Euro-Celtioue, S.A
Publication of TR200001706T2 publication Critical patent/TR200001706T2/tr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/28—Oxygen atom
    • C07D473/30—Oxygen atom attached in position 6, e.g. hypoxanthine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • Hospice & Palliative Care (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Compounds Of Unknown Constitution (AREA)

Abstract

Formül (i) 'in içerilmis bilesikleri olup;R3, C1-10 alkil,C1-10 alkenil, C3-10 sikloalkil, C4-10 sikloalkilalkil veya C3-10 sikloalkenilden olusan gruptan seçilmis olup bahsedilen alkil,alkenil, sikloalkil, sikloalkilalkil veya sikloalkenil opsiyonel olarak bir pozisyonda hidroksi veya benzil ile yer degistirmis; bahsedilen benzil opsiyonel olarak bir veya iki pozisyonda halojen, alkoksi, sikloalkoksi veya polisikloalkil ile yer degistirmis olup, bahsedilen ile bir pozisyonda yer degistirmistir; R8, hidrojen, C1-10 alkil,C1-10 alkenil, C3-10 sikloalkil, C4-10 sikloalkilalkil veya C3-10 sikloalkilalkil veya sikloalkenil opsiyonel olarak bir pozisyonda hidroksi veya benzil ile yer degistirmis olup, bahsedilen benzil opsiyonel olarak bir veya iki pozisyonda halojen,alkoksi veya siklo alkoksinin bahsedilen alkilin yarisi ile opsiyonel olarak bir pozisyonda hidroksi ile yer degistirmistir;R6a ve R6b, hidrojen, C1-10 alkil, C1-10 alkenil, C3-10 DEVAMI VAR
TR2000/01706T 1997-12-12 1998-12-11 Fosfodiester IV inhibisyonuna sahip purin türevleri TR200001706T2 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US6937197P 1997-12-12 1997-12-12

Publications (1)

Publication Number Publication Date
TR200001706T2 true TR200001706T2 (tr) 2000-11-21

Family

ID=22088545

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2000/01706T TR200001706T2 (tr) 1997-12-12 1998-12-11 Fosfodiester IV inhibisyonuna sahip purin türevleri

Country Status (19)

Country Link
US (5) US6037470A (tr)
EP (3) EP1044201A4 (tr)
JP (5) JP2002508377A (tr)
KR (3) KR100349385B1 (tr)
CN (3) CN1294590A (tr)
AT (1) ATE244243T1 (tr)
AU (5) AU1723099A (tr)
BR (3) BR9815170A (tr)
CA (3) CA2313004A1 (tr)
DE (3) DE19882893T1 (tr)
DK (1) DK1045849T3 (tr)
ES (1) ES2202924T3 (tr)
GB (2) GB2346878B (tr)
HU (3) HUP0301166A2 (tr)
NO (1) NO20002998L (tr)
PL (1) PL341108A1 (tr)
PT (1) PT1045849E (tr)
TR (1) TR200001706T2 (tr)
WO (5) WO1999031105A1 (tr)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002541078A (ja) * 1999-04-02 2002-12-03 ユーロ−セルティーク，エス．エー． ホスホジエステラーゼｉｖ阻害活性を有するプリン誘導体
CA2379356A1 (en) * 1999-08-12 2001-02-22 Mark Chasin Novel hypoxanthine and thiohypoxanthine compounds
BR0207302A (pt) * 2001-02-08 2004-02-10 Memory Pharm Corp Trifluorometilpurinas como inibidores da fosfodiesterase 4
FR2842809A1 (fr) * 2002-07-26 2004-01-30 Greenpharma Sas NOUVELLES PYRAZOLO[1,5-a]-1,3,5-TRIAZINES SUBSTITUEES ET LEURS ANALOGUES, COMPOSITIONS PHARMACEUTIQUES LES CONTENANT, UTILISATION A TITRE DE MEDICAMENT ET PROCEDES POUR LEUR PREPARATION
CA2494026A1 (en) * 2002-08-08 2004-02-19 Memory Pharmaceuticals Corporation Phosphodiesterase 4 inhibitors
US7332486B2 (en) * 2002-08-08 2008-02-19 Memory Pharmaceuticals Corp. Phosphodiesterase 4 inhibitors
US20040063938A1 (en) * 2002-09-30 2004-04-01 Pfizer Inc Process for preparing haloalkyl pyrimidines
OA13187A (en) * 2003-07-10 2006-12-13 Achillion Pharmaceuticals Inc Substituted arylthiourea derivatives useful as inhibitors of viral replication.
AR045134A1 (es) * 2003-07-29 2005-10-19 Smithkline Beecham Plc Compuesto de 1h - imidazo [4,5-c] piridin-ilo, composicion farmaceutica que lo comprende, proceso para prepararla, su uso para preparar dicha composicion farmaceutica, combinacion farmaceutica, uso de la combinacion farmaceutica para la preparacion de un medicamento, procedimientos para preparar dic
US20080280926A1 (en) * 2003-12-16 2008-11-13 Palle Venkata P Phosphodiesterase Inhibitors
EP2258358A3 (en) 2005-08-26 2011-09-07 Braincells, Inc. Neurogenesis with acetylcholinesterase inhibitor
CA2620333A1 (en) 2005-08-26 2007-03-01 Braincells, Inc. Neurogenesis by muscarinic receptor modulation
EP1940389A2 (en) 2005-10-21 2008-07-09 Braincells, Inc. Modulation of neurogenesis by pde inhibition
CA2625210A1 (en) 2005-10-31 2007-05-10 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
US7625890B2 (en) 2005-11-10 2009-12-01 Smithkline Beecham Corp. Substituted imidazo[4,5-c]pyridine compounds as Akt inhibitors
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
AU2007249399A1 (en) 2006-05-09 2007-11-22 Braincells, Inc. Neurogenesis by modulating angiotensin
MX2008014320A (es) 2006-05-09 2009-03-25 Braincells Inc Neurogenesis mediada por el receptor de 5-hidroxitriptamina.
DE102006033572A1 (de) 2006-07-20 2008-01-24 Bayer Cropscience Ag N'-Cyano-N-halogenalkyl-imidamid Derivate
MX2009002496A (es) 2006-09-08 2009-07-10 Braincells Inc Combinaciones que contienen un derivado de 4-acilaminopiridina.
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
UY30892A1 (es) 2007-02-07 2008-09-02 Smithkline Beckman Corp Inhibidores de la actividad akt
EP2235199A1 (en) 2007-12-17 2010-10-06 Lux Innovate Limited Compositions and methods for maintenance of fluid conducting and containment systems
AR075153A1 (es) * 2009-01-30 2011-03-16 Glaxosmithkline Llc Compuesto hidrocloruro de n-{(1s)-2-amino-1-[(3-fluorofenil)metil]etil)-5-cloro-4-(4-cloro-1-metil-1h-pirazol-5-il)-2- tiofenocarboxamida en forma cristalina, composicion farmaceitica que lo comprende, procedimiento para prepararla, su uso para preparar un medicamento util para tratar o disminuir la
US20100216805A1 (en) 2009-02-25 2010-08-26 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
PT3738434T (pt) 2011-12-28 2023-11-13 Global Blood Therapeutics Inc Intermediários para obter compostos de benzaldeído substituído e métodos para a sua utilização no aumento da oxigenação de tecidos
ES2790358T3 (es) 2011-12-28 2020-10-27 Global Blood Therapeutics Inc Compuestos de heteroaril aldehído sustituido y métodos para su uso en el aumento de la oxigenación tisular
EP2804603A1 (en) 2012-01-10 2014-11-26 President and Fellows of Harvard College Beta-cell replication promoting compounds and methods of their use
CA2902711C (en) 2013-03-15 2021-07-06 Global Blood Therapeutics, Inc. Substituted pyridinyl-6-methoxy-2-hydroxybenzaldehyde derivatives and pharmaceutical compositions thereof useful for the modulation of hemoglobin
US9422279B2 (en) 2013-03-15 2016-08-23 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
SG10201802911RA (en) 2013-03-15 2018-05-30 Global Blood Therapeutics Inc Compounds and uses thereof for the modulation of hemoglobin
US8952171B2 (en) 2013-03-15 2015-02-10 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US9458139B2 (en) 2013-03-15 2016-10-04 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
CN111454200A (zh) 2013-03-15 2020-07-28 全球血液疗法股份有限公司 化合物及其用于调节血红蛋白的用途
US10266551B2 (en) 2013-03-15 2019-04-23 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US10100043B2 (en) 2013-03-15 2018-10-16 Global Blood Therapeutics, Inc. Substituted aldehyde compounds and methods for their use in increasing tissue oxygenation
EA201992707A1 (ru) 2013-11-18 2020-06-30 Глобал Блад Терапьютикс, Инк. Соединения и их применения для модуляции гемоглобина
SI3102208T1 (sl) 2014-02-07 2021-07-30 Global Blood Therapeutics, Inc. Kristalinični polimorf proste baze 2-hidroksi-6-((2-(1-izopropil-1H-pirazol-5-IL)piridin-3-IL)metoksi)- benzaldehida
MA43373A (fr) 2015-12-04 2018-10-10 Global Blood Therapeutics Inc Régimes posologiques pour 2-hydroxy-6-((2- (1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)méthoxy)benzaldéhyde
WO2017123766A1 (en) * 2016-01-12 2017-07-20 Sperovie Biosciences, Inc. Compounds and compositions for the treatment of disease
TWI752307B (zh) 2016-05-12 2022-01-11 美商全球血液治療公司 新穎化合物及製造化合物之方法
TWI778983B (zh) 2016-10-12 2022-10-01 美商全球血液治療公司 包含2-羥基-6-((2-(1-異丙基-1h-吡唑-5-基)吡啶-3-基)甲氧基)-苯甲醛之片劑
US11014884B2 (en) 2018-10-01 2021-05-25 Global Blood Therapeutics, Inc. Modulators of hemoglobin
RU2746012C2 (ru) * 2019-05-13 2021-04-05 Федеральное государственное бюджетное образовательное учреждение высшего образования "Волгоградский государственный медицинский университет" Министерства здравоохранения Российской Федерации ФГБОУ ВО ВолгГМУ МЗ РФ Антидепрессантное средство для коррекции нежелательных побочных эффектов нейролептиков

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2956998A (en) 1960-10-18 Adenine derivatives and process
US2844577A (en) 1958-07-22 Certificate of correction
US3215696A (en) 1965-11-02 Substituted adenines -and preparation thereof
US2903455A (en) 1959-09-08 Jdnviiiiaisnvhi jo
US2697709A (en) 1951-06-14 1954-12-21 Burroughs Wellcome Co Mercapto heterocycles and method of making
US2691654A (en) 1952-06-11 1954-10-12 Buroughs Wellcome & Co U S A I Amino heterocycles and method of making
US2966488A (en) * 1956-07-30 1960-12-27 Shive William Substituted alkylaminopurines
US2957875A (en) 1957-11-18 1960-10-25 Upjohn Co Derivatives of purine
US3079378A (en) 1960-02-01 1963-02-26 Upjohn Co Acylated psicofuranosyladenines
NL262940A (tr) * 1960-03-31
US3135753A (en) 1961-05-10 1964-06-02 Burroughs Wellcome Co Alkylthiopurines and method
FR1548252A (tr) 1961-10-13 1968-12-06
IL24679A (en) * 1965-11-24 1971-10-20 Yissum Res Dev Co Derivatives of 3-methyl purine and methods of preparing the same
US3669979A (en) 1967-12-14 1972-06-13 Gaf Corp Novel process for the production of 2-benzothiazolyl-phenol and derivatives thereof employing phosphorus trichloride as a catalyst
US3952001A (en) 1970-07-01 1976-04-20 The Boots Company Limited 1-Carbamoyl-1,2,4-triazoles
JPS5121529A (ja) 1974-08-16 1976-02-20 Hitachi Ltd Pirorinsandometsukizeiseihimakuboshiho
USRE31429E (en) 1977-02-14 1983-10-25 Merck & Co., Inc. Process for preparation of 9-(dihalobenzyl)adenines
GB2041359B (en) * 1979-01-10 1982-12-15 Ici Ltd Purine derivatives and their use in the defoliation of cotton plants
US4241063A (en) 1979-08-06 1980-12-23 Bristol-Myers Company Purine derivatives and their use as bronchodilators
US4407802A (en) 1981-09-28 1983-10-04 Merck & Co., Inc. 6-Amidino-9-substituted benzyl purines
US4361699A (en) 1981-09-28 1982-11-30 Merck & Co., Inc. Novel process for the preparation of N6 -alkyl-arprinocid
GB2120065B (en) 1982-04-27 1986-01-02 Michael Frederick Huber Heating plants
US4492592A (en) 1983-06-06 1985-01-08 Shell Oil Company Combined desiccation of substantially supercritical CO2
JPS60260579A (ja) 1984-01-13 1985-12-23 Yoshitomi Pharmaceut Ind Ltd プリン誘導体
US4883801A (en) 1984-09-07 1989-11-28 The General Hospital Corporation Xanthine derivative pest control agents
GB8510758D0 (en) 1985-04-27 1985-06-05 Wellcome Found Compounds
WO1987006576A1 (en) 1986-04-29 1987-11-05 Pfizer Inc. Calcium independent camp phosphodiesterase inhibitor antidepressant
GB8618931D0 (en) 1986-08-02 1986-09-10 Euro Celtique Sa 6-thioxanthines
US5057517A (en) 1987-07-20 1991-10-15 Merck & Co., Inc. Piperazinyl derivatives of purines and isosteres thereof as hypoglycemic agents
US5091431A (en) 1988-02-08 1992-02-25 Schering Corporation Phosphodiesterase inhibitors
EP0363320A3 (de) 1988-10-06 1991-11-21 Ciba-Geigy Ag Substituierte 9H-Purine
US4971972A (en) 1989-03-23 1990-11-20 Schering Corporation Phosphodiesterase inhibitors having an optionally substituted purine derivative portion and a benzo- or cyclopenta-furan portion
US5290782A (en) 1989-09-01 1994-03-01 Kyowa Hakko Kogyo Co., Ltd. Xanthine derivatives
DE69033614T2 (de) 1989-10-20 2001-04-19 Kyowa Hakko Kogyo Kk Kondensierte Purinderivate
US5117830A (en) 1990-11-08 1992-06-02 Whitby Research, Inc. Method of determining viability of tissue
US5177074A (en) 1991-03-26 1993-01-05 Merck & Co., Inc. Angiotensin ii antagonists incorporating a substituted thiophene or furan
IL104369A0 (en) 1992-01-13 1993-05-13 Smithkline Beecham Corp Novel compounds and compositions
DE69322254T2 (de) 1992-01-13 1999-04-29 Smithkline Beecham Corp Pyridyl-substituierte imidazole
DE69309030T2 (de) 1992-06-15 1997-09-25 Celltech Therapeutics Ltd Trisubstituierte phenylderivate als selektive phosphodiesterase iv inhibitoren
MX9304571A (es) 1992-07-28 1994-05-31 Rhone Poulenc Rorer Ltd Compuestos fanilicos ligados a un arilo o heteroarilo mediante un radical alifatico o un atomo heterogeneo que contiene un grupo eslabonador.
GB9222253D0 (en) 1992-10-23 1992-12-09 Celltech Ltd Chemical compounds
ATE234270T1 (de) 1992-12-02 2003-03-15 Pfizer Cathecoldiether als selektive pde iv hemmungsmittel
GB9226830D0 (en) 1992-12-23 1993-02-17 Celltech Ltd Chemical compounds
TW263495B (tr) 1992-12-23 1995-11-21 Celltech Ltd
GB9304919D0 (en) 1993-03-10 1993-04-28 Celltech Ltd Chemical compounds
GB9304920D0 (en) 1993-03-10 1993-04-28 Celltech Ltd Chemical compounds
DE4309969A1 (de) 1993-03-26 1994-09-29 Bayer Ag Substituierte heteroanellierte Imidazole
GB9312853D0 (en) * 1993-06-22 1993-08-04 Euro Celtique Sa Chemical compounds
FI951367A (fi) 1994-03-28 1995-09-29 Japan Energy Corp Puriinijohdannaiset ja tulehdustautien tukahduttajat (suppressantit)
US5869486A (en) 1995-02-24 1999-02-09 Ono Pharmaceutical Co., Ltd. Fused pyrimidines and pyriazines as pharmaceutical compounds

Also Published As

Publication number Publication date
US6228859B1 (en) 2001-05-08
EP1045849A4 (en) 2001-10-31
DE69816127D1 (de) 2003-08-07
JP3504234B2 (ja) 2004-03-08
NO20002998D0 (no) 2000-06-09
WO1999031103A1 (en) 1999-06-24
GB2346879B (en) 2002-12-04
DE19882892T1 (de) 2001-02-22
DE69816127T2 (de) 2004-04-22
DE19882893T1 (de) 2001-02-22
NO20002998L (no) 2000-07-19
GB2346878B (en) 2002-12-04
HUP0301166A2 (en) 2003-08-28
JP2002508379A (ja) 2002-03-19
US6057445A (en) 2000-05-02
BR9815169A (pt) 2000-10-10
HUP0100417A2 (hu) 2001-12-28
AU747366B2 (en) 2002-05-16
WO1999029694A1 (en) 1999-06-17
CN1294590A (zh) 2001-05-09
EP1044201A4 (en) 2001-10-31
PL341108A1 (en) 2001-03-26
GB0013780D0 (en) 2000-07-26
US6211367B1 (en) 2001-04-03
CA2313004A1 (en) 1999-06-24
BR9815171A (pt) 2000-10-10
EP1044201A1 (en) 2000-10-18
GB2346879A (en) 2000-08-23
PT1045849E (pt) 2003-11-28
AU1815999A (en) 1999-07-05
CA2314335A1 (en) 1999-06-24
AU1722899A (en) 1999-07-05
DK1045849T3 (da) 2003-10-27
AU1722999A (en) 1999-07-05
ES2202924T3 (es) 2004-04-01
EP1045850A1 (en) 2000-10-25
AU1723099A (en) 1999-07-05
KR20010032979A (ko) 2001-04-25
WO1999031105A1 (en) 1999-06-24
CA2313150A1 (en) 1999-06-17
JP2002508377A (ja) 2002-03-19
EP1045849B1 (en) 2003-07-02
US6037470A (en) 2000-03-14
CN1281458A (zh) 2001-01-24
ATE244243T1 (de) 2003-07-15
GB2346878A (en) 2000-08-23
KR100349385B1 (ko) 2002-08-24
WO1999031102A1 (en) 1999-06-24
EP1045849A1 (en) 2000-10-25
EP1045850A4 (en) 2001-10-31
CN1284077A (zh) 2001-02-14
KR20010033049A (ko) 2001-04-25
JP2002508378A (ja) 2002-03-19
HUP0100417A3 (en) 2002-04-29
AU1820899A (en) 1999-06-28
JP2002508376A (ja) 2002-03-19
GB0013781D0 (en) 2000-07-26
HUP0100305A2 (hu) 2002-01-28
KR20010032681A (ko) 2001-04-25
JP2001525412A (ja) 2001-12-11
US6040447A (en) 2000-03-21
WO1999031104A1 (en) 1999-06-24
BR9815170A (pt) 2000-10-10

Similar Documents

Publication Publication Date Title
TR200001706T2 (tr) Fosfodiester IV inhibisyonuna sahip purin türevleri
DE69622031T2 (de) INDOLDERIVATE ALS cGMP-PDE INHIBITOREN
CY2473B1 (en) New phenanthridines.
DE69809754D1 (en) Substituierte 6-phenylphenanthridine
TR200003513T2 (tr) Pirolo[2,3d]Pirimidin kompozisyonları ve kullanımları
AU2291097A (en) Novel phenanthridines substituted in the 6 position
TR200000197T2 (tr) Yeni bileşimler
BG103251A (en) Oxydiazols, methods for their preparation and application as medicamentous forms
CY2509B1 (en) New thiazole derivatives with phosphodiesterase-inhibitting effect
DE69719778D1 (de) Benzonaphthyridine als bronchialtherapeutika
MX9702382A (es) Nuevos derivados de pirimidona con actividad antifungica.
PL338339A1 (en) Novel derivatives of tetrazole
TW254945B (tr)
PL339073A1 (en) Derivatives of benzoxazine and benzothiazine and their application in therapeutic agents
IL114968A0 (en) 1,4-dihydropyridine compounds
TR199902115T2 (tr) 2,3- Dihidrofuro (3,2-b) piridiun türevleri, hazirlanislari ve terapide uygulanmalari.
ZA981430B (en) Anticancer composition
CY2582B2 (en) New imidazopyridines and oxazolopyridines
TR200103042T2 (tr) N”rotrofin g‡lendiricileri
PT958290E (pt) Derivados de 1,4-di-hidropiridina e seu uso em terapia
IL132344A0 (en) Alkaloid halide salts of swainsonine compositions containing the same and the use thereof